Corteva (NYSE:CTVA) Price Target Raised to $95.00

Key Points

• Royal Bank of Canada raised its price target for Corteva (NYSE:CTVA) to $95 from $89 and kept an "outperform" rating, implying about a 21% upside from the prior close.
• Several other brokerages also lifted targets (e.g., Jefferies to $95, Wells Fargo to $90, CICC to $80), leaving a MarketBeat consensus of "Moderate Buy" with a consensus target of $85.19.
• Shares traded down to $78.50, below most analyst targets; Corteva has a market cap of $52.7B, a P/E of ~49.7, and set FY2026 guidance of 3.45–3.70 EPS (street estimate 3.62).

Corteva (NYSE:CTVA - Get Free Report) had its price target upped by equities research analysts at Royal Bank Of Canada from $89.00 to $95.00 in a research report issued to clients and investors on Friday, MarketBeat reports. The brokerage presently has an "outperform" rating on the stock. Royal Bank Of Canada's price objective would indicate a potential upside of 21.02% from the stock's previous close.

Several other brokerages have also recently issued reports on CTVA. CICC Research raised their target price on shares of Corteva from $70.00 to $80.00 and gave the stock an "outperform" rating in a report on Wednesday, February 11th. Berenberg Bank lifted their price target on shares of Corteva from $68.00 to $78.00 and gave the stock a "hold" rating in a research note on Thursday, March 26th. Jefferies Financial Group lifted their target price on shares of Corteva from $85.00 to $95.00 and gave the company a "buy" rating in a research note on Monday, March 2nd. Wells Fargo & Company boosted their target price on shares of Corteva from $85.00 to $90.00 and gave the stock an "overweight" rating in a report on Tuesday. Finally, Oppenheimer boosted their target price on shares of Corteva from $86.00 to $89.00 and gave the stock an "outperform" rating in a report on Wednesday. Fourteen equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, Corteva currently has a consensus rating of "Moderate Buy" and a consensus target price of $85.19.

Corteva Stock Down 1.4%

Shares of NYSE:CTVA traded down $1.13 during trading on Friday, reaching $78.50. 152,474 shares of the stock traded hands, compared to its average volume of 4,010,066. The stock has a 50-day moving average of $80.00 and a two-hundred day moving average of $71.49. Corteva has a 52-week low of $60.53 and a 52-week high of $85.63. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.96 and a current ratio of 1.43. The stock has a market cap of $52.70 billion, a P/E ratio of 49.73, a price-to-earnings-growth ratio of 2.72 and a beta of 0.68.

Corteva (NYSE:CTVA - Get Free Report) last posted its quarterly earnings results on Tuesday, February 3rd. The company reported $0.22 EPS for the quarter, meeting analysts' consensus estimates of $0.22. Corteva had a net margin of 6.29% and a return on equity of 9.06%. The firm had revenue of $3.91 billion for the quarter, compared to analysts' expectations of $4.23 billion. During the same quarter in the prior year, the company posted $0.32 earnings per share. The business's revenue for the quarter was down 1.7% on a year-over-year basis. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. As a group, sell-side analysts expect that Corteva will post 3.62 earnings per share for the current fiscal year.

Insider Activity at Corteva

In related news, insider Brian Titus sold 8,311 shares of Corteva stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $76.55, for a total transaction of $636,207.05. Following the completion of the transaction, the insider directly owned 8,090 shares of the company's stock, valued at approximately $619,289.50. The trade was a 50.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.15% of the company's stock.

Hedge Funds Weigh In On Corteva

A number of large investors have recently made changes to their positions in CTVA. Brighton Jones LLC boosted its position in Corteva by 307.2% in the 4th quarter. Brighton Jones LLC now owns 15,588 shares of the company's stock valued at $888,000 after buying an additional 11,760 shares during the period. Woodline Partners LP raised its stake in shares of Corteva by 40.3% during the 1st quarter. Woodline Partners LP now owns 57,919 shares of the company's stock worth $3,645,000 after acquiring an additional 16,644 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of Corteva by 62.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,559 shares of the company's stock worth $191,000 after acquiring an additional 980 shares in the last quarter. Cresset Asset Management LLC increased its stake in Corteva by 2.6% during the 2nd quarter. Cresset Asset Management LLC now owns 7,063 shares of the company's stock valued at $526,000 after purchasing an additional 181 shares in the last quarter. Finally, Jump Financial LLC purchased a new stake in Corteva during the second quarter worth $1,464,000. 81.54% of the stock is owned by hedge funds and other institutional investors.

Corteva Company Profile

Corteva, Inc NYSE: CTVA is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva's operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.